Incyte Q1 Results Top Estimates

RTTNews | hace 1191
Incyte Q1 Results Top Estimates

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $161.43 million or $0.72 per share for the first quarter, up from $149.46 million or $0.67 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $1.01 per share, compared to $0.80 per share in the year-ago quarter.

Total revenues for the quarter rose 29 percent to $911.40 million from $705.71 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.76 per share on revenues of $818.49 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2022, Incyte now projects Jakafi net product revenue in a range of $2.36 billion to $2.40 billion. Other Hematology/Oncology net product revenues are projected between $210 million and $240 million.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.
RTTNews | hace 631
Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).
RTTNews | hace 957
Australian Market Halves Its Early Gains In Mid-market

Australian Market Halves Its Early Gains In Mid-market

The Australian market is halving its early gains in mid-market moves on Thursday, reversing some of the losses in the previous two sessions, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving above the 8,800 level, with gains across most sectors led by mining and energy stocks amid rebounding commodity prices.
RTTNews | hace 2h 6min
Asian Markets Track Wall Street Higher

Asian Markets Track Wall Street Higher

Asian markets are trading mostly higher on Thursday, following the broadly positive cues from Wall Street overnight, as some traders looked to pick up stocks at reduced levels following the recent sell-off. Traders also react to upbeat private US economic data and growing expectations that the US Supreme Court may reject the Trump administration's aggressive trade policy.
RTTNews | hace 2h 33min
Japanese Market Sharply Higher

Japanese Market Sharply Higher

The Japanese market is sharply higher on Thursday, snapping a five-session losing streak, following the broadly positive cues from Wall Street overnight. The Nikkei 225 is moving up almost 2 percent to above the 50,900 level, with gains across most sectors led by index heavyweights, exporters and financial stocks.
RTTNews | hace 2h 57min
Thai Stock Market May Reclaim 1,300-Point Plateau

Thai Stock Market May Reclaim 1,300-Point Plateau

The Thai stock market has moved lower in five straight sessions, slumping more than 15 points or 1.2 percent along the way. The Stock Exchange of Thailand now sits just shy of the 1,300-point plateau although it's expected to open to the upside on Thursday.
RTTNews | hace 3h 29min
Additional Support Anticipated For Indonesia Shares

Additional Support Anticipated For Indonesia Shares

The Indonesia stock market has alternated between positive and negative finishes through the last four trading days since the end of the two-day winning streak in which it had picked up almost 100 points or 1.2 percent. The Jakarta Composite Index now sits just beneath the 8,320-point plateau and it may add to its winnings on Thursday.
RTTNews | hace 3h 59min